专题：Pharmaceutical Economics and Policy

This cluster of papers explores the economics of pharmaceutical research and development, focusing on topics such as drug development costs, generic drugs, pharmaceutical innovation, medicine prices, patent expiry, healthcare policies, market size, availability of medicines, and generic substitution.
最新文献
Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements

article Full Text OpenAlex

Impact of China’s National Drug Price Negotiation Policy on Availability, Affordability, and Regional Equity of Negotiated Drugs: A Multidimensional Nationwide Analysis, 2018 to 2021

article Full Text OpenAlex

Early access disparities in innovative therapies across the US, EU, China, and Japan

article Full Text OpenAlex

Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy

article Full Text OpenAlex

Psychopharmacology: The ‘Combo Pills’-Did it find its way into Practice?

article Full Text OpenAlex

The UK must defend drug price controls

editorial Full Text OpenAlex

From Lab to Clinic: Success Stories of Repurposed Drugs in Treating Major Diseases

article Full Text OpenAlex

Dollars and dilemmas: lenacapavir’s pricing, patents, and the path to affordability

letter Full Text OpenAlex

Exploring the Lack of Transparency in Prescription Drug Costs: Contributors and Avenues for Reform

editorial Full Text OpenAlex

Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities

article Full Text OpenAlex

近5年高被引文献
Indian Journal of Pharmaceutical Education and Research

paratext Full Text OpenAlex 357 FWCI0

Vaccines safety case studies

book-chapter Full Text OpenAlex 332 FWCI85.85477716

World Health Organization model list of essential medicines for children 8th list, 2021

article Full Text OpenAlex 323 FWCI277.4650913

Polypill Strategy in Secondary Cardiovascular Prevention

article Full Text OpenAlex 286 FWCI89.08978175

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

article Full Text OpenAlex 276 FWCI138.52729068

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

article Full Text OpenAlex 275 FWCI81.03397367

Improving data on pharmaceutical expenditure in hospitals and other health care settings

report Full Text OpenAlex 254 FWCI0

Navigating financial toxicity in patients with cancer: A multidisciplinary management approach

review Full Text OpenAlex 231 FWCI53.34782497

Drug repurposing: a systematic review on root causes, barriers and facilitators

review Full Text OpenAlex 214 FWCI54.77633483

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations

article Full Text OpenAlex 209 FWCI47.57425084